AGI-5198

製品コードS7185 バッチS718501

印刷

化学情報

Chemical Structure Synonyms IDH-C35 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C27H31FN4O2
分子量 462.56 CAS No. 1355326-35-0
Solubility (25°C)* 体外 DMSO 24 mg/mL (51.88 mM)
Ethanol 14 mg/mL (30.26 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
in vitro AGI-5198, potently inhibits mutant IDH1 (R132H-IDH1 and R132C-IDH1), but not wildtype IDH1 (IC50 > 100 μM) or any of IDH2 isoforms (R140Q, R172K, wildtype) (IC50 > 100 μM). This compound has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to block R-2HG production in a dose-dependent manner. Under conditions of near-complete R-2HG inhibition, it induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mIDH1 impaired the growth of IDH1-mutant—but not IDH1–wild-type—glioma cells without appreciable changes in genome-wide DNA methylation. [1]
in vivo In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) causes 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts. Tumors from this compound-treated mice shows reduced staining with an antibody against the Ki-67 protein. But cleaved caspase-3 shows no differences between tumors from vehicle and this chemical–treated mice. [1]

プロトコル(参考用のみ)

キナーゼアッセイ IDH enzyme activity
Compound is prepared as 10 mM stock in DMSO and diluted to 50X final concentration in DMSO, for a 50 μL reaction mixture. IDH enzyme activity converting alpha-ketogluta rate to 2-hydroxyglutarate is measured using a NADPH depletion assay. In the assay the remaining cofactor is measured at the end of the reaction with the addition of a catalytic excess of diaphorase and resazurin, to generate a fluorescent signal in proportion to the amount of NADPH remaining. IDH enzyme activity in the direction of isocitrate to alpha-ketoglutarate conversion is measured by direct coupling of the NADPH production to conversion of resazurin to resorufin by diaphorase. In both cases, resorufin is measured fluorometrically at Ex544 Em 590.
細胞アッセイ 細胞株 TS603
濃度 0, 23.4, 93.8, 375, 3000 nM
反応時間 --
実験の流れ

soft-agar colony formation
動物実験 動物モデル IDH1 mutant glioma xenografts
投薬量 150 mg/kg, 450 mg/kg per day
投与方法 gavage

参考

  • https://pubmed.ncbi.nlm.nih.gov/23558169/

カスタマーフィードバック

Data from [Data independently produced by , , J BIOL CHEM, 2018, doi:10.1074/jbc.RA117.001385]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML [ EMBO Mol Med, 2025, 10.1038/s44321-025-00296-2] PubMed: 40883610
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [ EBioMedicine, 2024, 102:105090] PubMed: 38547578
High-Content and High-Throughput Clonogenic Survival Assay Using Fluorescence Barcoding [ Cancers -Basel), 2023, 15(19)4772] PubMed: 37835466
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia [ Cancer Cell, 2022, S1535-6108(22)00312-9] PubMed: 35868306
Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation [ Cancer Res, 2022, 82(3):497-509] PubMed: 34737211
Strategies for Targeting DNA Damage Repair and Overcoming Drug Resistance in IDH Mutant Cancers [ Yale University, 2022, 29396067] PubMed: None
Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells [ Cancer Discov, 2020, CD-20-0226] PubMed: 32606138
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells [ Cancer Discov, 2020, 10(11):1672-1689] PubMed: 32606138
Triptolide Suppresses IDH1-mutated Malignancy via Nrf2-driven Glutathione Metabolism [ Proc Natl Acad Sci U S A, 2020, 5;117(18):9964-9972] PubMed: 32312817
IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR. [ Oncol Lett, 2020, 19(2):1322-1330] PubMed: 31966064

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。